Authors: Renato De Natale,¹; Lafuma, Antoine²; Berdeaux, Gilles³

Source: Clinical Drug Investigation, Volume 29, Number 2, 2009 , pp. 111-120(10)

Publisher: Adis International

Abstract:

Objective: This study aimed to compare the cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol as first-line therapies for ocular hypertension or glaucoma.

Methods: Patient charts were extracted from the UK General Practitioner Research Database. Patients with ocular hypertension or glaucoma who received first-line treatment with either travoprost or latanoprost/timolol and were followed up for >6 months were included. Treatment failure was defined as a treatment change or a glaucoma intervention (laser therapy or surgery). Time to treatment failure was compared using a Cox model and adjusted by the propensity score method.

Results: Eligible patients received either travoprost (n = 639) or latanoprost/timolol (n = 176). Their mean age was 70 years at diagnosis and 48.2% of patients were male. Patient characteristics did not differ significantly between treatment groups. Treatment failure rates at 1 year were 31.3% (travoprost) and 39.4% (latanoprost/timolol) and yielded a hazard ratio for failure in favour of travoprost (0.75; p < 0.04) after adjusting for age, sex, co-morbidities and duration of follow-up. Adjusted annual costs of glaucoma management were significantly (p < 0.001) less with travoprost (£215.86) than with latanoprost/timolol (£327.83).

Conclusions: In everyday practice, travoprost was maintained longer than latanoprost/timolol as first-line therapy for glaucoma. The mean daily costs of travoprost were 50.8% less per patient than those of latanoprost/timolol. Despite adjustments, these results might be confounded, at least partially, by disease severity.

Keywords: Antiglaucomas; Cost effectiveness; Fixed combinations; Glaucoma; Latanoprost/timolol; Ocular hypertension; Travoprost

Document Type: Research article

Affiliations: 1: 1 U.O. Oculistica di Monselice, Padova, Italy 2: 2 Cemka Eval, Bourg-la-Reine, France 3: 3 Alcon France, Rueil-Malmaison, France

Publication date: 2009-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Renato De Natale, ;  Lafuma, Antoine ;  Berdeaux, Gilles

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers